Pinnacle Associates Ltd. Boosts Holdings in Novo Nordisk A/S $NVO

Pinnacle Associates Ltd. increased its position in shares of Novo Nordisk A/S (NYSE:NVO) by 40.3% in the 3rd quarter, Holdings Channel reports. The firm owned 51,022 shares of the company’s stock after purchasing an additional 14,660 shares during the period. Pinnacle Associates Ltd.’s holdings in Novo Nordisk A/S were worth $2,831,000 at the end of the most recent reporting period.

Other hedge funds also recently bought and sold shares of the company. Revolve Wealth Partners LLC lifted its position in Novo Nordisk A/S by 8.7% in the fourth quarter. Revolve Wealth Partners LLC now owns 2,490 shares of the company’s stock valued at $214,000 after buying an additional 200 shares during the last quarter. AQR Capital Management LLC raised its position in Novo Nordisk A/S by 21.0% in the 1st quarter. AQR Capital Management LLC now owns 62,099 shares of the company’s stock valued at $4,312,000 after purchasing an additional 10,758 shares in the last quarter. Sivia Capital Partners LLC raised its holdings in Novo Nordisk A/S by 18.2% in the second quarter. Sivia Capital Partners LLC now owns 10,320 shares of the company’s stock valued at $712,000 after acquiring an additional 1,587 shares in the last quarter. Savant Capital LLC lifted its position in shares of Novo Nordisk A/S by 3.0% during the 2nd quarter. Savant Capital LLC now owns 13,932 shares of the company’s stock worth $962,000 after purchasing an additional 403 shares during the last quarter. Finally, Parkside Financial Bank & Trust lifted its holdings in Novo Nordisk A/S by 24.9% during the 2nd quarter. Parkside Financial Bank & Trust now owns 2,867 shares of the company’s stock worth $198,000 after buying an additional 571 shares during the last quarter. Institutional investors and hedge funds own 11.54% of the company’s stock.

Novo Nordisk A/S Stock Down 2.6%

Novo Nordisk A/S stock opened at $38.73 on Wednesday. The company has a debt-to-equity ratio of 0.61, a current ratio of 0.80 and a quick ratio of 0.57. Novo Nordisk A/S has a 1-year low of $35.85 and a 1-year high of $82.57. The company has a market cap of $172.92 billion, a PE ratio of 11.16 and a beta of 0.73. The stock’s 50 day moving average price is $50.93 and its 200 day moving average price is $52.11.

Novo Nordisk A/S (NYSE:NVO) last issued its quarterly earnings data on Tuesday, February 3rd. The company reported $1.01 EPS for the quarter, beating analysts’ consensus estimates of $0.90 by $0.11. The firm had revenue of $12.43 billion for the quarter, compared to analysts’ expectations of $11.97 billion. Novo Nordisk A/S had a net margin of 33.03% and a return on equity of 68.91%. On average, sell-side analysts predict that Novo Nordisk A/S will post 3.84 EPS for the current fiscal year.

Novo Nordisk A/S Dividend Announcement

The business also recently disclosed a dividend, which will be paid on Wednesday, April 8th. Shareholders of record on Monday, March 30th will be given a $1.2751 dividend. The ex-dividend date of this dividend is Monday, March 30th. This represents a yield of 541.0%. Novo Nordisk A/S’s dividend payout ratio (DPR) is 23.63%.

More Novo Nordisk A/S News

Here are the key news stories impacting Novo Nordisk A/S this week:

• Positive Sentiment: Capacity and production investment — Novo is expanding manufacturing in Ireland with ~ $506m to raise oral GLP‑1 output to meet global demand, which supports longer‑term volume growth and supply resilience. Novo expands manufacturing (InsiderMonkey)
• Positive Sentiment: Distribution partnership — Novo agreed to supply Wegovy/Ozempic through Hims & Hers’ telehealth platform, ending a legal dispute and opening a digital channel that could broaden U.S. access and sales. That deal helped calm one litigation front and may support volume. Novo-Hims deal (Reuters)
• Positive Sentiment: Share repurchase — Novo confirmed ongoing share buybacks (part of up to DKK15bn programme), which is supportive for shareholder returns and EPS. Share repurchase programme (GlobeNewswire)
• Neutral Sentiment: Past earnings vs. guidance — Novo beat Q4 consensus on revenue and EPS but earlier issued weak FY2026 guidance that pressured the stock; investors now weigh strong recent results against management’s cautious full‑year outlook. Q4 results & guidance (Seeking Alpha)
• Negative Sentiment: FDA warning letter — The U.S. FDA issued a warning letter after an inspection tied to Plainsboro (early 2025) citing failures in post‑marketing safety reporting for semaglutide products; the regulator flagged potential unreported adverse events including two deaths and a suicide — a material safety/regulatory risk that spooked investors. FDA warning (Reuters) Potential unreported side effects (Forbes)
• Negative Sentiment: Legal / investor risk — A law firm (Pomerantz) has launched an investigation on behalf of investors, increasing potential litigation/legal-cost overhangs. Investor investigation (GlobeNewswire)
• Negative Sentiment: Analyst downgrades and pipeline concerns — TD Cowen cut NVO to Hold and other analysts flagged the pipeline as “not poised to blunt semaglutide loss‑of‑exclusivity” and rising competitive pressure from new GLP‑1 entrants, pressuring forward expectations and valuation. Pipeline downgrade (Yahoo Finance)
• Negative Sentiment: Market reaction / sector weakness — Healthcare indices were weaker intraday as investors rotated away from GLP‑1 names amid safety/regulatory headlines and heightened competition; that broad sentiment hit NVO alongside the specific company news. Sector decline (Yahoo Finance)

Analyst Upgrades and Downgrades

Several equities analysts have issued reports on the company. BMO Capital Markets reaffirmed a “market perform” rating on shares of Novo Nordisk A/S in a report on Thursday, February 5th. TD Cowen cut Novo Nordisk A/S from a “buy” rating to a “hold” rating and set a $42.00 price objective for the company. in a research report on Tuesday. HSBC reiterated a “hold” rating and issued a $54.00 target price on shares of Novo Nordisk A/S in a research note on Wednesday, December 10th. Deutsche Bank Aktiengesellschaft downgraded Novo Nordisk A/S from a “buy” rating to a “hold” rating in a report on Monday, February 23rd. Finally, Kepler Capital Markets lowered shares of Novo Nordisk A/S from a “buy” rating to a “hold” rating in a research report on Tuesday, February 24th. Four analysts have rated the stock with a Buy rating, eighteen have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Hold” and an average price target of $49.93.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.